Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database

被引:112
作者
Allott, Emma H. [1 ,2 ,3 ]
Howard, Lauren E. [1 ,3 ,4 ]
Cooperberg, Matthew R. [5 ]
Kane, Christopher J. [6 ]
Aronson, William J. [7 ,8 ]
Terris, Martha K. [9 ,10 ]
Amling, Christopher L. [11 ]
Freedland, Stephen J. [1 ,3 ,12 ]
机构
[1] Duke Univ, Sch Med, Dept Surg, Div Urol, Durham, NC 27710 USA
[2] Duke Canc Inst, Canc Prevent Detect & Control Program, Durham, NC USA
[3] Vet Affairs Med Ctr Durham, Div Urol, Durham, NC USA
[4] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC 27710 USA
[5] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA
[6] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA
[7] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA
[8] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA
[9] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA
[10] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA
[11] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA
[12] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA
关键词
HIGH-DENSITY-LIPOPROTEIN; METABOLIC SYNDROME; HDL CHOLESTEROL; STATIN USE; GRADE; ASSOCIATION; PREVENTION; OBESITY; COHORT; MEN;
D O I
10.1158/1055-9965.EPI-14-0458
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Evidence for an association between total cholesterol, low- and high-density lipoproteins (LDL and HDL, respectively), triglycerides, and prostate cancer is conflicting. Given that prostate cancer and dyslipidemia affect large proportions of Western society, understanding these associations has public health importance. Methods: We conducted a retrospective cohort analysis of 843 radical prostatectomy (RP) patients who never used statins before surgery within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analysis was used to investigate the association between cholesterol, LDL, HDL, and triglycerides and biochemical recurrence risk. In secondary analysis, we explored these associations in patients with dyslipidemia, defined using National Cholesterol Education Program guidelines. Results: Elevated serum triglycerides were associated with increased risk of prostate cancer recurrence [HRper 10mg/dl, 1.03; 95% confidence interval (CI), 1.01-1.05] but associations between total cholesterol, LDL and HDL, and recurrence risk were null. However, among men with dyslipidemia, each 10 mg/dl increase in cholesterol and HDL was associated with 9% increased recurrence risk (HR, 1.09; 95% CI, 1.01-1.17) and 39% reduced recurrence risk (HR, 0.61; 95% CI, 0.41-0.91), respectively. Conclusions: Elevated serum triglycerides were associated with increased risk of prostate cancer recurrence. Cholesterol, LDL, or HDL were not associated with recurrence risk among all men. However, among men with dyslipidemia, elevated cholesterol and HDL levels were associated with increased and decreased risk of recurrence, respectively. Impact: These findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels should be explored as a modifiable risk factor for prostate cancer recurrence. (C) 2014 AACR.
引用
收藏
页码:2349 / 2356
页数:8
相关论文
共 32 条
  • [1] Prediagnostic Total and High-Density Lipoprotein Cholesterol and Risk of Cancer
    Ahn, Jiyoung
    Lim, Unhee
    Weinstein, Stephanie J.
    Schatzkin, Arthur
    Hayes, Richard B.
    Virtamo, Jarmo
    Albanes, Demetrius
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (11) : 2814 - 2821
  • [2] Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database
    Allott, E. H.
    Abern, M. R.
    Gerber, L.
    Keto, C. J.
    Aronson, W. J.
    Terris, M. K.
    Kane, C. J.
    Amling, C. L.
    Cooperberg, M. R.
    Moorman, P. G.
    Freedland, S. J.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (04) : 391 - 397
  • [3] Allott EH., 2014, BJU Int
  • [4] Obesity and Prostate Cancer: Weighing the Evidence
    Allott, Emma H.
    Masko, Elizabeth M.
    Freedland, Stephen J.
    [J]. EUROPEAN UROLOGY, 2013, 63 (05) : 800 - 809
  • [5] Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study
    Batty, G. David
    Kivimaeki, Mika
    Clarke, Robert
    Smith, George Davey
    Shipley, Martin J.
    [J]. CANCER CAUSES & CONTROL, 2011, 22 (02) : 311 - 318
  • [6] High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States
    Colli, Janet L.
    Amling, Christopher L.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (02) : 170 - 173
  • [7] The metabolic syndrome - A high-risk state for cancer?
    Cowey, Stephanie
    Hardy, Robert W.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (05) : 1505 - 1522
  • [8] Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population
    Farwell, Wildon R.
    D'Avolio, Leonard W.
    Scranton, Richard E.
    Lawler, Elizabeth V.
    Gaziano, J. Michael
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (11): : 885 - 892
  • [9] Prevalence and Trends in Obesity Among US Adults, 1999-2008
    Flegal, Katherine M.
    Carroll, Margaret D.
    Ogden, Cynthia L.
    Curtin, Lester R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (03): : 235 - 241
  • [10] Fryar Cheryl D, 2012, Natl Health Stat Report, P1